Clinical trials: Adnexal Tumor
Cancer
Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
The purpose of this study is to determine the safety and tolerability of the drug SOR-C13 when given as an intravenous infusion in patients with ovarian cancer or other cancers known to over express the TRPV6 calcium channel.
- Trial name
- NCT01578564
- Testing
- SOR-C13
- Where
- 3 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Soricimed Biopharma Inc
Ovarian Cancer, Endometrial Cancer
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
The purpose of this study is to test the safety of the investigational drug, selinexor (KPT-330), in combination with carboplatin and paclitaxel chemotherapy, where paclitaxel will be given at two different dosing schedules and…
- Trial name
- NCT02269293
- Testing
- Paclitaxel, Carboplatin, Selinexor
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Ovarian cancer is the leading cause of gynecologic cancer deaths, and the fifth most common cause of cancer deaths in women. While approximately 75% of patients with epithelial ovarian cancer will respond to first-line…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01610206
- Testing
- Gemcitabine, pazopanib
- Where
- 8 sites in United States
- Volunteers
- 148 people
- Sponsor
- Linda R Duska
Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm.
- Conditions
- Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer, Platinum-Resistant FRα-Positive Peritoneal Cancer
- Trial name
- MIRELA (NCT07896421)
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- AbbVie
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum.
- Conditions
- Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8
- Trial name
- NCT04095364
- Testing
- Biopsy Procedure, Biospecimen Collection, Carboplatin
- Where
- 909 sites in United States, Canada and 4 more
- Volunteers
- 450 people
- Sponsor
- NRG Oncology
Ovarian Cancer, Ovarian Cancer Recurrent
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer.
- Trial name
- MAIA-ovarian (NCT06888921)
- Testing
- COM701, Normal Saline
- Where
- 27 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Compugen Ltd
Ovarian Cancer
ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
The purpose of the study is to investigate the combination VS-6063, carboplatin, and paclitaxel. in the treatment of patients with ovarian cancer.
- Trial name
- NCT03287271
- Testing
- VS-6063, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Michael McHale
Ovarian Neoplasms, Recurrent Ovarian Carcinoma
Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer
This is a prospective, multicenter, Phase II study aimed at defining the activity and safety of SBRT in MPR-OC. Clinical and imaging data as well as SBRT parameters would be analyzed with the aim to identify potential predictors…
- Conditions
- Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Oligometastatic Disease
- Trial name
- MITO-RT3/RAD (NCT04593381)
- Testing
- Stereotactic body radiotherapy
- Where
- 14 sites in Italy
- Volunteers
- 376 people
- Sponsor
- Gemelli Molise Hospital
Breast Cancer, Lung Cancer
Pillars4Life Trial
This study aims to explore whether cancer patients can benefit from completing the Pillars4Life online coping program. This randomized control trial will have half its subject completing the program and the other half receiving…
- Conditions
- Breast Cancer, Lung Cancer, Esophageal Cancer, Colon Cancer
- Trial name
- Pillars4Life (NCT02465892)
- Testing
- Pillars4Life
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- Duke University
Ovarian Cancer
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
This is non randomised, open label, dose finding, efficacy and safety study, enrolling patients with advanced (stage III and IV) ovarian cancer It will be conducted in two successive phases. Phase II has a two-step design
- Trial name
- NCT00831636
- Testing
- CP-4055
- Where
- 5 sites in Belgium, Italy
- Volunteers
- 28 people
- Sponsor
- Clavis Pharma
Polycystic Ovary Syndrome
Serum Anti-mullerian Hormone and Polycystic Ovarian Syndrome
In 1935 the polycystic ovary syndrome was a clinical diagnosis made on the morphological appearance of the ovaries in association with amenorrhoea, hirsutism and frequently obesity.
- Trial name
- NCT03237312
- Testing
- Laparoscopic ovarian drilling, Antimullerian hormone
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Ovarian Neoplasm
Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery
This is a single-center, randomized, phase II, non-comparative, single-blind clinical study that will determine whether morphine reduction through intraoperative monitoring by ANI (Analgesia Nociception Index) significantly…
- Trial name
- MONIALC (NCT04906187)
- Testing
- Arm A : intraoperative ANI monitoring of nociception, Arm B : no specific monitoring of nociception
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Institut Bergonié
Polycystic Ovary Syndrome, Infertility
Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome
It was randomised controlled study to compare the efficacy of clomiphene and letrozole in polycystic ovarian syndrome(PCOS) women with infertility.The aim was to select more appropriate treatment for ovulation induction in PCOS…
- Trial name
- NCT05702957
- Testing
- letrozole 2.5mg-7.5mg, Clomiphene Citrate 50mg-150mg
- Where
- Pakistan
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Neoplasms
Study of ADH-1 Given Intravenously to Patients With Solid Tumors
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00265057
- Testing
- ADH -1 (Exherin™)
- Where
- 3 sites in Italy, Switzerland
- Sponsor
- Adherex Technologies, Inc.
Polycystic Ovary Syndrome
Clomiphene Stair-Step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome
The objective of our study is to evaluate the efficacy of the clomiphene stair-step protocol to induce ovulation in women with polycystic ovarian syndrome (PCOS) compared to traditional protocol.
- Trial name
- PCOSCCTvUSS (NCT01953796)
- Testing
- clomiphene
- Where
- Iraq
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Kufa University
Infertility and at High Risk of OHSS
Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome
Gonadotropin releasing hormone (GnRH) agonist is sufficient for triggering final oocyte maturation in GnRH antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (OHSS) in high-risk…
- Trial name
- NCT02022241
- Testing
- triptorelin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chenshiling
Ovarian Cancer Recurrent, Endometrial Cancer Recurrent
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
This is a non-interventional, real-world study divided into two parts: a retrospective study and a prospective study. The main question it aims to answer is: Will genomic sequencing and molecular tumor boards lead to clinical…
- Conditions
- Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent
- Trial name
- RWS-MTB (NCT06781151)
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Ovarian Neoplasms, Ovarian Cancer
Improved Diagnosis of Ovarian Cancer
After implementation of systematic image description of adnexal masses, we aim to improve and evaluate our use of available imaging methods and biomarkers for classifying adnexal masses and distinguishing between benign and…
- Conditions
- Ovarian Neoplasms, Ovarian Cancer, Ovarian Cysts, Adnexal Mass
- Trial name
- NCT05842629
- Where
- Denmark
- Volunteers
- 1,700 people
- Sponsor
- University of Aarhus
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This phase I trial studies the side effects of genetically modified T cells and decitabine in treating patients with recurrent or refractory epithelial or non-epithelial ovarian, primary peritoneal, or fallopian tube cancer that…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03017131
- Testing
- Aldesleukin, Cyclophosphamide, Decitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.